Compare · NVO vs QUCY
NVO vs QUCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Mainz Biomed N.V. (QUCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and QUCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1884.5x QUCY ($114.3M).
- Over the past year, NVO is down 12.1% and QUCY is down 17.2% - NVO leads by 5.1 points.
- QUCY has been more active in the news (18 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for QUCY).
- Company
- Novo Nordisk A/S
- Mainz Biomed N.V.
- Price
- $48.65+3.65%
- $1.38+4.17%
- Market cap
- $215.46B
- $114.3M
- 1M return
- -2.08%
- +24.43%
- 1Y return
- -12.07%
- -17.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 18
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest QUCY
- Quantum Cyber Appoints Veteran Distribution Executive Dennis Schnur as Head of U.S. Sales as Company Advances Toward Commercialization of Domestic Drone Production
- Quantum Cyber Rejects Threat of Future Publications from Short-Seller Adam Gefvert Demanding Withdrawal of $5.69 Million Lawsuit
- Quantum Cyber to Participate in Invitation-Only 1640 Society Hamptons Family Office Wealth Forum 2026
- SEC Form 10-Q filed by Mainz Biomed N.V.
- Quantum Cyber Unveils the Quantum Photonic Antenna and Publishes Inaugural Technical White Paper Detailing the Quantum Layer of Its Autonomous Defense Platform
- SEC Form 4 filed by Chief Financial Officer Caragol William J
- Quantum Cyber Files Lawsuit Against White Diamond Research, Adam Gefvert and Stocktwits, Inc. in New York Supreme Court
- Chief Executive Officer Lazar David E. converted options into 55,057,500 units of Ordinary Shares (SEC Form 4)
- Amendment: SEC Form 4 filed by Director O'Rourke Peter
- Amendment: SEC Form 4 filed by Director Natan David